Cantor Fitzgerald Forecasts Weaker Earnings for Precigen

Precigen, Inc. (NASDAQ:PGEN) – Equities researchers at Cantor Fitzgerald lowered their FY2026 EPS estimates for Precigen in a report issued on Friday, September 26th. Cantor Fitzgerald analyst J. Kim now expects that the biotechnology company will post earnings of $0.06 per share for the year, down from their prior estimate of $0.07. The consensus estimate for Precigen’s current full-year earnings is ($0.32) per share.

Precigen (NASDAQ:PGEN) last announced its quarterly earnings results on Tuesday, August 12th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.03. Precigen had a negative net margin of 2,868.66% and a negative return on equity of 842.83%. The company had revenue of $0.86 million for the quarter, compared to analysts’ expectations of $0.67 million.

PGEN has been the topic of several other research reports. HC Wainwright reiterated a “buy” rating and set a $8.50 price target on shares of Precigen in a research report on Tuesday, August 19th. JPMorgan Chase & Co. upgraded shares of Precigen from an “underweight” rating to a “neutral” rating in a research report on Friday, August 15th. Wall Street Zen upgraded shares of Precigen from a “sell” rating to a “hold” rating in a research report on Saturday, July 12th. JMP Securities boosted their price target on shares of Precigen from $6.00 to $8.00 and gave the company a “market outperform” rating in a research report on Tuesday, August 19th. Finally, Citigroup reiterated an “outperform” rating on shares of Precigen in a research report on Tuesday, August 19th. Four equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, Precigen presently has a consensus rating of “Moderate Buy” and a consensus price target of $8.25.

Precigen Price Performance

Shares of NASDAQ PGEN opened at $3.51 on Monday. Precigen has a 1 year low of $0.65 and a 1 year high of $5.22. The company’s 50-day moving average is $3.11 and its 200 day moving average is $2.07. The stock has a market capitalization of $1.05 billion, a P/E ratio of -8.36 and a beta of 1.81.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in PGEN. BNP Paribas Financial Markets bought a new position in shares of Precigen in the fourth quarter worth approximately $27,000. Apella Capital LLC bought a new position in shares of Precigen in the first quarter worth approximately $40,000. Voya Investment Management LLC lifted its stake in shares of Precigen by 142.9% in the first quarter. Voya Investment Management LLC now owns 36,771 shares of the biotechnology company’s stock worth $55,000 after buying an additional 21,633 shares in the last quarter. ProShare Advisors LLC lifted its position in Precigen by 26.6% during the fourth quarter. ProShare Advisors LLC now owns 51,822 shares of the biotechnology company’s stock valued at $58,000 after purchasing an additional 10,900 shares during the period. Finally, Strs Ohio bought a new position in Precigen during the first quarter valued at approximately $70,000. Institutional investors own 33.51% of the company’s stock.

Insider Buying and Selling

In other news, Director Randal J. Kirk sold 3,596,892 shares of the company’s stock in a transaction that occurred on Friday, September 19th. The shares were sold at an average price of $3.68, for a total value of $13,236,562.56. Following the transaction, the director owned 8,520,537 shares in the company, valued at approximately $31,355,576.16. This represents a 29.68% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Harry Jr. Thomasian bought 8,284 shares of the company’s stock in a transaction dated Thursday, September 25th. The stock was purchased at an average price of $3.62 per share, for a total transaction of $29,988.08. Following the purchase, the chief financial officer owned 465,694 shares of the company’s stock, valued at approximately $1,685,812.28. This represents a 1.81% increase in their position. The disclosure for this purchase can be found here. Insiders have acquired 52,221 shares of company stock valued at $207,667 over the last quarter. Corporate insiders own 47.10% of the company’s stock.

About Precigen

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.